Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Datasets
Prizes
Spin-Offs
Activities
Media
Search by expertise, name or affiliation
Neo- oder adjuvante Chemotherapie beim Harnblasenkarzinom?
Translated title of the contribution
:
Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?
M. C. Hupe
, M. W. Kramer, M. A. Kuczyk,
A. S. Merseburger
*
*
Corresponding author for this work
Clinic of Urology
Urologische Klinik
Hannover Medical School
1
Citation (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Adjuvant Chemotherapy
100%
Neoadjuvant Chemotherapy
100%
Bladder Cancer
100%
Cisplatin
66%
Neoplasm
33%
Metastatic Carcinoma
33%
Lymph Node
33%
Bladder
33%
Transitional Cell Carcinoma
33%
Metastasis Potential
33%
Gemcitabine
33%
Therapeutic Agent
33%
Metastasectomy
33%
Methotrexate
33%
Doxorubicin
33%
Vinblastine
33%
Vinflunine
33%
Pharmacology, Toxicology and Pharmaceutical Science
Cisplatin
100%
Bladder Cancer
100%
Doxorubicin
50%
Vinblastine
50%
Methotrexate
50%
Vinflunine
50%
Neoplasm
50%
Metastasis Potential
50%
Transitional Cell Carcinoma
50%
Gemcitabine
50%